Drug Discovery for Schistosomiasis: Hit and Lead Compounds Identified in a Library of Known Drugs by Medium-Throughput Phenotypic Screening
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Praziquantel (PZQ) is the only widely available drug to treat schistosomiasis. Given the potential for drug resistance, it is prudent to search for novel therapeutics. Identification of anti-schistosomal chemicals has traditionally relied on phenotypic (whole organism) screening with adult worms in vitro and/or animal models of disease-tools that limit automation and throughput with modern microtiter plate-formatted compound libraries. METHODS: A partially automated, three-component phenotypic screen workflow is presented that utilizes at its apex the schistosomular stage of the parasite adapted to a 96-well plate format with a throughput of 640 compounds per month. Hits that arise are subsequently screened in vitro against adult parasites and finally for efficacy in a murine model of disease. Two GO/NO GO criteria filters in the workflow prioritize hit compounds for tests in the animal disease model in accordance with a target drug profile that demands short-course oral therapy. The screen workflow was inaugurated with 2,160 chemically diverse natural and synthetic compounds, of which 821 are drugs already approved for human use. This affords a unique starting point to 'reposition' (re-profile) drugs as anti-schistosomals with potential savings in development timelines and costs. FINDINGS: Multiple and dynamic phenotypes could be categorized for schistosomula and adults in vitro, and a diverse set of 'hit' drugs and chemistries were identified, including anti-schistosomals, anthelmintics, antibiotics, and neuromodulators. Of those hits prioritized for tests in the animal disease model, a number of leads were identified, one of which compares reasonably well with PZQ in significantly decreasing worm and egg burdens, and disease-associated pathology. Data arising from the three components of the screen are posted online as a community resource. CONCLUSIONS: To accelerate the identification of novel anti-schistosomals, we have developed a partially automated screen workflow that interfaces schistosomula with microtiter plate-formatted compound libraries. The workflow has identified various compounds and drugs as hits in vitro and leads, with the prescribed oral efficacy, in vivo. Efforts to improve throughput, automation, and rigor of the screening workflow are ongoing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 2×
“repositioning (re-profiling or re-purposing) [30] chemical entities as novel anti-schistosomals.”
BackgroundSteinmann, P., Keiser, J., Bos, R., Tanner, M., & Utzinger, J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70521-7 · Cited by 2,156 · cited 1×
“Yet, reliance on a single drug to treat a population of over 200 million people infected and over 700 million people at risk over three continents [9] seems particularly perilous when considering the threat of drug resistance.”
BackgroundControl of Neglected Tropical Diseases
Hotez, P. J., Molyneux, D. H., Fenwick, A., Kumaresan, J., Sachs, S. E., Sachs, J. D., & Savioli, L. (2007) · New England Journal of Medicine · doi:10.1056/nejmra064142 · Cited by 1,585
An Improved Perfusion Technique for Recovering Adult Schistosomes from Laboratory Animals
Duvall, R. H., & DeWitt, W. B. (1967) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1967.16.483 · Cited by 599 · cited 1×
“the hepatic portal system [34] in RPMI 1640 medium (Invitrogen, Carlsbad, CA).”
MethodOpportunities and Challenges in Antiparasitic Drug Discovery
Pink, R., Hudson, A., Mouriès, M.-A., & Bendig, M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1824 · Cited by 545 · cited 1×
“[6].”
Innovative lead discovery strategies for tropical diseases
Nwaka, S., & Hudson, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2144 · Cited by 521 · cited 5×
“demand for short course oral chemotherapy [29].”
BackgroundMethodInfluentialPraziquantel, a new broad-spectrum antischistosomal agent
G�nnert, R., & Andrews, P. (1977) · Zeitschrift f�r Parasitenkunde · doi:10.1007/bf00389899 · Cited by 412 · cited 1×
“seems particularly perilous when considering the threat of drug resistance. Also, PZQ is not without problems. Principal among these is its relative inactivity against migratory juvenile and sub-adult worms”
BackgroundSchistosoma mansoni: Chemotherapy of infections of different ages
Sabah, A. A., Fletcher, C., Webbe, G., & Doenhoff, M. J. (1986) · Experimental Parasitology · doi:10.1016/0014-4894(86)90184-0 · Cited by 360 · cited 1×
“Principal among these is its relative inactivity against migratory juvenile and sub-adult worms [10,11] meaning that, for effective treatment and sustainable control, PZQ must be given on a regular basis.”
BackgroundThe biology and toxicology of molluscicides, bayluscide
Andrews, P., Thyssen, J., & Lorke, D. (1982) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(82)90064-x · Cited by 347
Cioli, D., & Pica-Mattoccia, L. (2003) · Parasitology Research · doi:10.1007/s00436-002-0751-z · Cited by 343
Drug discovery and development for neglected parasitic diseases
Renslo, A. R., & McKerrow, J. H. (2006) · Nature Chemical Biology · doi:10.1038/nchembio837 · Cited by 337 · cited 3×
“‘public-private partnership’ (PPP) consortia [7,8] are ongoing to”
BackgroundResultSelf-citationSchistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control
Utzinger, J., & Keiser, J. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.2.263 · Cited by 329 · cited 1×
“Thus, recent discussions, as part of treatment landscape for human helminthiases in general [12], have focused on reawakening the need to search for alternatives to PZQ, including the development of combinations of drugs incorporating PZQ [13,14].”
BackgroundBasch, P. F. (1981) · The Journal of Parasitology · doi:10.2307/3280632 · Cited by 325 · cited 1×
“The water is poured off and replaced with 9 mL ice-cold ‘Incomplete’ Medium 169 ([35]; custom made at the UCSF Cell Culture Facility) that contains 16penicillin-streptomycin solution.”
BackgroundA clinical drug library screen identifies astemizole as an antimalarial agent
Chong, C. R., Chen, X., Shi, L., Liu, J. O., & Sullivan, D. J. (2006) · Nature Chemical Biology · doi:10.1038/nchembio806 · Cited by 289 · cited 4×
“Finally, the collections contain a chemically diverse set of natural and synthetic small molecules, 41% (821 compounds) of which are drugs already FDA-approved.”
BackgroundInfluentialFasciolicides: Efficacy, Actions, Resistance and its Management
FAIRWEATHER, I., & BORAY, J. C. (1999) · The Veterinary Journal · doi:10.1053/tvjl.1999.0377 · Cited by 280 · cited 2×
“We identified a number that are wellestablished in the veterinary sector and possess better oral bioavailability with systemic anthelmintic activity, including against related trematode parasites [42].”
BackgroundChemotherapy of schistosomiasis: present and future
Caffrey, C. R. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.05.031 · Cited by 277 · cited 1×
“Thus, recent discussions, as part of treatment landscape for human helminthiases in general [12], have focused on reawakening the need to search for alternatives to PZQ, including the development of combinations of drugs incorporating PZQ [13,14].”
BackgroundSelf-citationIdentification of oxadiazoles as new drug leads for the control of schistosomiasis
Sayed, A. A., Simeonov, A., Thomas, C. J., Inglese, J., Austin, C. P., & Williams, D. L. (2008) · Nature Medicine · doi:10.1038/nm1737 · Cited by 270 · cited 2×
“TPP for any new-anti-schistosomal calls for short course therapy [15,29].”
BackgroundSchistosomiasis Mansoni: Novel Chemotherapy Using a Cysteine Protease Inhibitor
Abdulla, M.-H., Lim, K.-C., Sajid, M., McKerrow, J. H., & Caffrey, C. R. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040014 · Cited by 269 · cited 6×
“The outer two columns (1 and 12) of each screen plate are kept empty for eventual manual addition of the anti-schistosomal compounds, PZQ and the cysteine protease inhibitor, K777 [16], each at 1 and 5 mM.”
BackgroundMethodInfluentialSelf-citationDoenhoff, M. J., & Pica-Mattoccia, L. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.2.199 · Cited by 203 · cited 1×
“The bar is high - PZQ decreases worm burdens by between 60 and 90% in a single oral dose [3,48].”
BackgroundMefloquine—An Aminoalcohol with Promising Antischistosomal Properties in Mice
Keiser, J., Chollet, J., Xiao, S.-H., Mei, J.-Y., Jiao, P.-Y., Utzinger, J., & Tanner, M. (2009) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000350 · Cited by 201
MARTIN, R. J., ROBERTSON, A. P., & BJORN, H. (1997) · Parasitology · doi:10.1017/s0031182097001029 · Cited by 175
Schistosoma mansoni: Simplified method for the production of schistosomules
Colley, D. G., & Wikel, S. K. (1974) · Experimental Parasitology · doi:10.1016/0014-4894(74)90005-8 · Cited by 160 · cited 1×
“Cercariae are mechanically transformed into schistosomula by passing back and forth between two 10 mL syringes attached via a 22-gauge double-headed needle (adapted from [36]).”
BackgroundA comparative study of the life-histories of mammalian schistosomes
Loker, E. S. (1983) · Parasitology · doi:10.1017/s0031182000052689 · Cited by 153 · cited 1×
“mouse model [28]).”
Artemisinins and synthetic trioxolanes in the treatment of helminth infections
Keiser, J., & Utzinger, J. (2007) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3282f19ec4 · Cited by 152 · cited 2×
“and mature parasites has already shown value with the artemisinin class of compounds ([14] and references therein).”
BackgroundCurrent status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt
Botros, S. S., Sayed, H. A. E., Amer, N. M., El-Ghannam, M., Bennett, J. L., & Day, T. A. (2005) · International Journal for Parasitology · doi:10.1016/j.ijpara.2005.02.005 · Cited by 128 · cited 1×
“and widespread resistance, despite occasional and isolated incidences [4], has yet to occur.”
BackgroundSearching for New Antimalarial Therapeutics amongst Known Drugs
Weisman, J. L., Liou, A. P., Shelat, A. A., Cohen, F. E., Guy, R. K., & DeRisi, J. L. (2006) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2006.00391.x · Cited by 127 · cited 2×
“The same collections have already provided a number of leads against other parasites [31,32,33].”
BackgroundDiscovery of Trypanocidal Compounds by Whole Cell HTS of Trypanosoma brucei
Mackey, Z. B., Baca, A. M., Mallari, J. P., Apsel, B., Shelat, A. A., Hansell, E. J., Chiang, P. K., Wolff, B. E., Guy, R. K., Williams, J. A., et al. (2006) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2006.00389.x · Cited by 121 · cited 2×
“The same collections have already provided a number of leads against other parasites [31,32,33].”
BackgroundSelf-citationCaffrey, C. R., Rohwer, A., Oellien, F., Marhöfer, R. J., Braschi, B., Oliveira, G., McKerrow, J. H., & Selzer, P. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004413 · Cited by 112 · cited 2×
“mansoni [18,19], one might envisage RNA interference of candidate cholinergic, dopaminergic or seratonergic receptors in an effort to modulate the overactive phenotype.”
BackgroundSelf-citationFavennec, L., Ortiz, J. J., Gargala, G., Chegne, N. L., Ayoub, A., & Rossignol, J. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01419.x · Cited by 111 · cited 1×
“Nitazoxanide (marketed as Alinia) is approved for the treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia and has shown efficacy against human fascioliasis hepatica [45].”
BackgroundPreliminary trials with praziquantel in human infections due to Schistosoma mansoni.
Katz, N., Rocha, R. S., & Chaves, A. C. (1979) · PubMed · Cited by 95
Studies on the toxicity of gambogic acid in rats
Qi, Q., You, Q., Gu, H.-Y., Zhao, L., Liu, W., Lu, N., & Guo, Q. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.02.027 · Cited by 81 · cited 1×
“Gambogic acid, a xanthone isolated from various species of the Garcinia tree, was recently shown to be non-toxic in rats after oral administration every other day for 13 weeks at 30 and 60 mg/kg in 2% carboxymethylcellulose-sodium [40].”
BackgroundSchistosomicidal activity of the antimalarial drug, mefloquine, in Schistosoma mansoni-infected mice
Nassauw, L. V., Toovey, S., den bosch, J. V. O., Timmermans, J., & Vercruysse, J. (2008) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2008.06.006 · Cited by 73 · cited 1×
“, [22,23]), or for which bioactivity has been characterized in other parasitological or biomedical settings [24,25,26].”
BackgroundMalignant glioma drug discovery – targeting protein kinases
Sathornsumetee, S., Vredenburgh, K. A., Lattimore, K. P., & Rich, J. N. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.1.1 · Cited by 66
Harder, A. (2002) · Parasitology Research · doi:10.1007/s00436-001-0587-y · Cited by 56
Recent initiatives and strategies to developing new drugs for tropical parasitic diseases
Caffrey, C. R., & Steverding, D. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.2.173 · Cited by 44 · cited 7×
“The intent is to streamline and accelerate the identification of anti-schistosomal compounds by interfacing the helminth with the microtiter plate (96- and/or 384well) formatted compound libraries and associated robotic liquid handling systems now standard in industry and many academic institutions, and routinely empl…”
BackgroundResultInfluentialSelf-citationSchistosoma mansoni genome: Closing in on a final gene set
Haas, B. J., Berriman, M., Hirai, H., Cerqueira, G. G., LoVerde, P. T., & El-Sayed, N. M. (2007) · Experimental Parasitology · doi:10.1016/j.exppara.2007.06.005 · Cited by 43 · cited 2×
“Hopefully, this paucity of targets can be better addressed with the recent availability of the draft genomes of both Schistosoma mansoni [18] and S.”
BackgroundAnthelmintic discovery and development in the animal health industry
Woods, D. J., Lauret, C., & Geary, T. G. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.s1.s25 · Cited by 43 · cited 1×
“Most often, the compounds originated in the animal health sector as part of its discovery programs to identify veterinary antiparasitics [46,47].”
Background
Cited by
Controlling schistosomiasis with praziquantel: How much longer without a viable alternative?
Bergquist, R., Utzinger, J., & Keiser, J. (2017) · Infectious Diseases of Poverty · doi:10.1186/s40249-017-0286-2 · Cited by 195
“[85] tested a large number of natural and synthetic compounds against S.”
Background“Manifesto” for Advancing the Control and Elimination of Neglected Tropical Diseases
Hotez, P. J., & Pecoul, B. (2010) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000718 · Cited by 138
(2025) · doi:10.1073/pnas.2505710122 · Cited by 8
Metadata
- Authors
- Abdulla, M.-H., Ruelas, D. S., Wolff, B., Snedecor, J., Lim, K.-C., Xu, F., Renslo, A. R., Williams, J., McKerrow, J. H., & Caffrey, C. R.
- Venue
- PLoS Neglected Tropical Diseases
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-07-14
- Volume
- 3
- Issue
- 7
- Pages
- e478
- ISSN
- 1935-2727 (ISSN-L)
- 1935-2735
- OpenAlex
- W2055907171
- Cited by
- 224
- References
- 37
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.